Examining the Durability of HIV Regimens
Katia Boven, MD, Head of Clinical Development and Global Medical Affairs, Infectious Diseases, Janssen, discussed results and impact of the SWORD clinical trial involving the investigational two-drug combination being as effective as the three or four regimens as maintenance therapy in HIV patients who have already achieved viral suppression.
Phase 3 Trial of Ibalizumab ART Therapy Reports Positive Results
"Even though we have a lot of drugs, because of the resistance profile of their virus, they don't have a lot of options, so what these results mean for the most vulnerable of our patients is that they have access now to a new class of drugs," Emu concluded.
HIV's Greatest Success: Preventing Transmission from Mothers-To-Babies
James McIntyre, MBChB, FRCOG, continued to discuss the key success story in HIV prevention history: preventing transmission from mothers to babies. Many papers report that transmission has dropped to less than 2%, and across Africa transmission has dropped from 18% to less than 6%.